stoxline Quote Chart Rank Option Currency Glossary
  
EyePoint Pharmaceuticals, Inc. (EYPT)
8.66  0.03 (0.35%)    10-07 13:36
Open: 8.65
High: 8.66
Volume: 182,093
  
Pre. Close: 8.63
Low: 8.37
Market Cap: 463(M)
Technical analysis
2024-10-07 1:12:27 PM
Short term     
Mid term     
Targets 6-month :  10.41 1-year :  11.35
Resists First :  8.91 Second :  9.72
Pivot price 8.42
Supports First :  7.61 Second :  6.33
MAs MA(5) :  8.35 MA(20) :  8.47
MA(100) :  9.12 MA(250) :  14.59
MACD MACD :  -0.1 Signal :  -0.2
%K %D K(14,3) :  40.1 D(3) :  31.5
RSI RSI(14): 52.1
52-week High :  30.98 Low :  5.67
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ EYPT ] has closed below upper band by 39.7%. Bollinger Bands are 48.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 56 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.71 - 8.73 8.73 - 8.76
Low: 8.21 - 8.24 8.24 - 8.28
Close: 8.57 - 8.62 8.62 - 8.68
Company Description

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Headline News

Sun, 06 Oct 2024
Renaissance Technologies LLC Increases Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat

Fri, 04 Oct 2024
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $30.57 Consensus Price Target from Analysts - MarketBeat

Mon, 16 Sep 2024
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan

Thu, 29 Aug 2024
EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade) - Seeking Alpha

Sat, 10 Aug 2024
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance

Fri, 09 Aug 2024
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 54 (M)
Shares Float 36 (M)
Held by Insiders 1.4 (%)
Held by Institutions 110.1 (%)
Shares Short 9,100 (K)
Shares Short P.Month 9,480 (K)
Stock Financials
EPS -1.78
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.38
Profit Margin -172.3 %
Operating Margin -364.6 %
Return on Assets (ttm) -24.4 %
Return on Equity (ttm) -60.9 %
Qtrly Rev. Growth 4 %
Gross Profit (p.s.) 0
Sales Per Share 0.94
EBITDA (p.s.) -1.81
Qtrly Earnings Growth 0 %
Operating Cash Flow -90 (M)
Levered Free Cash Flow -33 (M)
Stock Valuations
PE Ratio -4.83
PEG Ratio 0
Price to Book value 1.95
Price to Sales 9.11
Price to Cash Flow -5.13
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android